Man, you are good. That is probably what is going on with Finbar.
Isiscat2011 said
Sep 11, 2014
New info regarding Olysio drug interactions with immunosuppressants:
On September 5, 2014, FDA approved revisions to the OLYSIO (simeprevir) label to update section 7: Drug Interactions and section 12: Clinical Pharmacology with new data and recommendations regarding coadministration of simeprevir and the immunosuppressants cyclosporing and tacrolimus.
Specifically the following was added to section 7:
Cyclosporine:Concomitant use of OLYSIO with cyclosporine resulted in significantly increased plasma concentrations of simeprevir due to inhibition of OATP1B1, P-gp and CYP3A by cyclosporine. It is not recommended to co-administer OLYSIO with cyclosporine.
Tacrolimus: Concomitant use of OLYSIO with tacrolimus resulted in increased plasma concentrations of simeprevir due to inhibition of OATP1B1. No dose adjustment is required for either drug when OLYSIO is co-administered with tacrolimus. Routine monitoring of blood concentrations of tacrolimus is acceptable.
Section 12 was updated to provide the results of the drug-drug interaction trials with cylcosporine and tacrolimus.
-- Edited by Isiscat2011 on Thursday 11th of September 2014 09:45:41 PM
Man, you are good. That is probably what is going on with Finbar.
New info regarding Olysio drug interactions with immunosuppressants:
On September 5, 2014, FDA approved revisions to the OLYSIO (simeprevir) label to update section 7: Drug Interactions and section 12: Clinical Pharmacology with new data and recommendations regarding coadministration of simeprevir and the immunosuppressants cyclosporing and tacrolimus.
Specifically the following was added to section 7:
Cyclosporine:Concomitant use of OLYSIO with cyclosporine resulted in significantly increased plasma concentrations of simeprevir due to inhibition of OATP1B1, P-gp and CYP3A by cyclosporine. It is not recommended to co-administer OLYSIO with cyclosporine.
Tacrolimus: Concomitant use of OLYSIO with tacrolimus resulted in increased plasma concentrations of simeprevir due to inhibition of OATP1B1. No dose adjustment is required for either drug when OLYSIO is co-administered with tacrolimus. Routine monitoring of blood concentrations of tacrolimus is acceptable.
Section 12 was updated to provide the results of the drug-drug interaction trials with cylcosporine and tacrolimus.
-- Edited by Isiscat2011 on Thursday 11th of September 2014 09:45:41 PM